Zepbound vs Ozempic: Which Works Better?

Zepbound vs Ozempic is one of the most searched GLP-1 comparisons, and the first thing to understand is that these are two different molecules with two different FDA approvals: Zepbound is tirzepatide from Eli Lilly, approved for chronic weight management, while Ozempic is semaglutide from Novo Nordisk, approved for type 2 diabetes. Both are once-weekly subcutaneous injections, both reduce appetite, and both carry a list price near or above $1,000 a month. But because one drug is licensed for weight and the other for blood sugar, comparing Zepbound vs Ozempic purely on pounds lost is partly apples to oranges. This guide walks through mechanism, approvals, dosing, efficacy, side effects, and cost, then explains which one a prescriber is likely to reach for and why.

Zepbound vs Ozempic at a glance

The table below is the head-to-head summary. Every row is unpacked in the sections that follow.

Drug	Active ingredient	Maker	FDA-approved use	Mechanism	Dose range	Average weight loss in trials	Typical list price
Zepbound	Tirzepatide	Eli Lilly	Chronic weight management (approved November 2023); also obstructive sleep apnea in adults with obesity	Dual agonist at GIP and GLP-1 receptors	2.5 mg starting dose, then 5, 7.5, 10, 12.5, 15 mg weekly	Up to about 20.9% mean body-weight loss over 72 weeks (SURMOUNT-1)	About $1,086 per month
Ozempic	Semaglutide	Novo Nordisk	Type 2 diabetes in adults; plus reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease	Single GLP-1 receptor agonist	0.25 mg for the first 4 weeks, then 0.5, 1, 2 mg weekly	Not a weight-management indication; semaglutide 2.4 mg produced about 14.9% over 68 weeks in STEP-1	About $997 per month

Why Zepbound vs Ozempic is partly apples to oranges

This is the caveat that most Zepbound vs Ozempic comparisons skip. Ozempic is dosed for glycemic control, with a 2 mg weekly ceiling. Zepbound is dosed for weight, climbing to 15 mg weekly. Novo Nordisk sells a separate semaglutide product, Wegovy, that is dosed at 2.4 mg specifically for weight management. So the cleaner molecule-to-molecule, purpose-to-purpose comparison is Zepbound versus Wegovy, which we cover in Wegovy vs Zepbound. Comparing Zepbound to Ozempic still tells you something useful, but you are comparing a drug designed and titrated for weight loss against a drug designed and titrated for diabetes.

The other honest caveat is that the headline percentages come from different trials, in different populations, run at different times. SURMOUNT-1 enrolled adults with obesity or overweight without diabetes. STEP-1 did something similar for semaglutide, but it is a separate study with its own protocol. Cross-trial percentages are indicative, not a scoreboard.

Mechanism: dual agonist versus single GLP-1 receptor agonist

Semaglutide, the molecule in Ozempic, is a GLP-1 receptor agonist. It mimics the gut hormone GLP-1, which slows gastric emptying, increases satiety signalling, and improves glucose-dependent insulin release. Tirzepatide, the molecule in Zepbound, does that too, but it is a dual agonist: it activates both the GIP receptor and the GLP-1 receptor. That extra GIP activity is the leading explanation for why tirzepatide tends to produce a larger average weight effect than semaglutide.

Practically, this means Zepbound vs Ozempic is not a branding difference or a price tier. They are structurally different drugs. If you want the pharmacology without the brand names, see tirzepatide vs semaglutide, which compares the two molecules directly.

FDA approvals: weight management versus type 2 diabetes

Zepbound was FDA-approved in November 2023 for chronic weight management in adults, and it later gained an approval for obstructive sleep apnea in adults with obesity. Ozempic is approved for type 2 diabetes in adults, along with an approval to reduce major cardiovascular events in adults who have type 2 diabetes and established cardiovascular disease.

Ozempic is not approved for weight loss. Prescribing it for weight alone is off-label, which is legal but consequential: off-label use is usually not covered by insurance, so a patient prescribed Ozempic for weight is frequently paying list price. That single fact shapes more real-world Zepbound vs Ozempic decisions than any trial result does.

Dosing and titration

Both drugs are weekly subcutaneous injections, and both are titrated slowly to limit gastrointestinal side effects.

• Zepbound: starts at 2.5 mg weekly, then steps to 5, 7.5, 10, 12.5, and a maximum of 15 mg, escalated roughly every 4 weeks as tolerated. Full detail in our Zepbound dosage guide.
• Ozempic: starts at 0.25 mg weekly for the first 4 weeks, which is a tolerability dose rather than a treatment dose, then 0.5 mg, 1 mg, and a maximum of 2 mg. Full detail in our Ozempic dosage chart.

Notice that the two dose ladders are not comparable in milligrams. Tirzepatide 15 mg is not "seven times stronger" than semaglutide 2 mg, because they are different molecules with different potencies. Milligram numbers only mean something within a single drug.

Efficacy: what the trials actually show

In SURMOUNT-1, tirzepatide produced up to about 20.9% mean body-weight loss over 72 weeks. In STEP-1, semaglutide 2.4 mg produced about 14.9% over 68 weeks. Again, those are separate trials, so the gap is suggestive rather than definitive.

There is one closer read: the SURMOUNT-5 head-to-head trial compared tirzepatide and semaglutide directly for weight, with tirzepatide landing around 20% and semaglutide around 14%. That trial compared the molecules at weight-management dosing, not Zepbound against Ozempic specifically, so it still does not answer the Ozempic question directly. What it does support is the general pattern: as a class, the dual agonist tends to outperform the single GLP-1 receptor agonist on weight.

Averages also hide enormous individual variation. Some people on semaglutide lose more than the tirzepatide average, and some people on tirzepatide lose very little. For a broader view across the class, see GLP-1 weight loss results by drug.

Side effects and safety

On tolerability, Zepbound vs Ozempic is close. Both share the same GLP-1-driven side-effect profile, and both are worst during dose escalation:

• Nausea, the most commonly reported effect for both
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

These typically ease as the body adapts to a given dose, which is exactly why both products titrate upward slowly rather than starting at a therapeutic dose.

Both drugs also carry a boxed warning for thyroid C-cell tumors observed in rodents, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Pancreatitis and gallbladder problems are labeled risks for both. These are prescriber-level screening questions, not something to work through alone.

Cost and insurance coverage

List prices are close: Zepbound runs about $1,086 per month and Ozempic about $997 per month. Eli Lilly's LillyDirect sells Zepbound single-dose vials for self-pay patients from roughly $349 to $499 per month. All of these figures are approximate and change frequently, so verify current pricing directly with the manufacturer or pharmacy.

Coverage, not list price, is what most people actually experience. Because Ozempic is a diabetes drug, plans that cover diabetes medications often cover it for a patient with type 2 diabetes, sometimes at a modest copay. Because Zepbound is a weight-management drug, coverage depends on whether the plan includes an obesity or anti-obesity medication benefit at all, and many do not. That asymmetry can flip the practical Zepbound vs Ozempic math entirely. See Zepbound cost per month and Ozempic price without insurance for the route-by-route breakdown.

Which one is likely prescribed for you

This is a clinical decision, not a shopping decision. Prescribers generally reason from diagnosis first, then history, then coverage:

• If you have type 2 diabetes, a semaglutide product such as Ozempic is a standard, on-label option, and the cardiovascular indication may matter if you also have established cardiovascular disease.
• If the treatment target is obesity or overweight with a weight-related condition, an on-label weight-management drug such as Zepbound fits the indication, and the sleep apnea approval can be relevant for some patients.
• If your history includes medullary thyroid carcinoma, MEN 2, pancreatitis, or gallbladder disease, that may rule out both drugs or change the plan.
• If your plan covers one and not the other, that constraint often decides the practical outcome regardless of trial percentages.

Nothing here is a reason to change what you are taking. Switching between these drugs is a prescriber decision, and it means restarting titration on the new molecule from its lowest dose, plus re-checking coverage under a different benefit category.

The short answer on Zepbound vs Ozempic

For weight loss specifically, the evidence favors tirzepatide over semaglutide, so Zepbound generally outperforms Ozempic on that single measure, and the dual GIP and GLP-1 mechanism is the leading explanation. But Ozempic is not a weight-loss drug, and evaluating it as one misreads what it is licensed to do. If the real question is which weight-management injection works better, the fair matchup is Zepbound versus Wegovy. If the real question is which drug you should be on, that depends on your diagnosis, your medical history, and your insurance, and only a prescriber can answer it.

This article is educational and is not medical advice. Zepbound and Ozempic are prescription medications with boxed warnings, contraindications, and meaningful side effects. Only a licensed prescriber can decide whether either drug is appropriate for you, at what dose, and for how long. Never start, stop, or switch a GLP-1 medication on your own. Prices and approvals change; verify current details with the manufacturer, your pharmacy, and your insurer.